PRXL2B

Across TCGA pan-cancer cohorts, PRXL2B RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of PRXL2B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PRXL2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRXL2B is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, STAD, and KICH are the cancer types where PRXL2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRXL2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.790	<.001	9	view →
STAD	Male	II,III,IV	+1.633	<.001	9	view →
KICH	Female	II,III,IV	−1.932	<.001	8	view →
BRCA	All	III,IV	+0.924	<.001	6	view →
BLCA	All	All	+0.812	.001	6	view →
HNSC	All	All	+0.585	<.001	6	view →
LUAD	All	II,III,IV	+0.468	.002	6	view →
COAD	All	II,III,IV	+0.290	.002	6	view →
CHOL	Male	All	+2.838	<.001	5	view →
ESCA	All	II,III,IV	+3.094	.006	4	view →
KIRP	All	IV	+0.912	.009	3	view →
PAAD	All	All	+1.077	.024	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

PRXL2B–LIHC

Open the LIHC breakdown →